TATVA CHINTAN PHARMA CHEM LTD Q3 RESULTS
Stock market update: Nifty Pharma index falls 0.92%
The Nifty Pharma index closed 0.92 per cent down at 18796.3.
Q4 results this week: Adani group to lead as 211 companies will declare earnings
With 211 companies announcing quarterly results this week, investors are particularly watching out for major names like Kotak Mahindra Bank, DMart, Ultratech Cement, Indian Oil, and many others across various industries.
Buy Tatva Chintan Pharma Chem, target price Rs 1590: Prabhudas Lilladher
Tatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 2851.61 Crore) operating in Chemicals sector.
These 26 companies saw over 25% drop in Q3 sales, PAT; are they still worth betting on?
Around 26 companies, with a market capitalisation of over Rs 2,500 crore, reported atleast 25% year-on-year (YoY) fall in both revenue and profits in the last quarter, and a majority of them were part of the chemicals and pesticides sector.
3 sectors on radar where we will buy on 15-20-25-40% fall : Vinay Jaising
India's dependence on global markets for liquidity has reduced, with retail India providing strong inflows. rising US yields will not have a severe impact on India, as the country is more resilient and has seen higher interest rates in the past. Indian markets may be sideways in the medium term, but quarterly results and earnings growth will drive market performance. JM Financial Services is researching and keeping an eye on opportunities in the finsumption, capex, and Make in India sectors.
Stocks of these 21 cos tumble over 20% in 1 year as profits slump for 4 straight quarters
At least 21 Indian companies with a market cap of over INR 5bn ($66m) saw their profits decline in each of the past four quarters and their stocks suffer negative returns in the last year, according to ET Markets. Five of the companies belong to the pharmaceutical sector, while three operate in specialty chemicals. Laxmi Organic Industries saw net profit fall by 37-66% YoY in the last four consecutive quarters, while Motilal Oswal Financial Services's profit fell 45% and 86% in the March and June quarters, respectively. Experts have recommended that investors focus on domestic sectors in the coming quarter while global growth remains lukewarm.
- Go To Page 1
6 smallcap stocks with high ROE & consistent return on capital employed
Investing in small cap stocks is one of the toughest challenges for any investor. However, if an investor gets his decision right, the returns on investment on getting (ROI) are high. ET screener powered by Refinitiv’s Stock Report Plus lists down stocks from small cap space with high upside potential over the next 12 months, having an average recommendation rating of “Buy” or "Strong Buy" and also meeting some parameters like net margins and return on equity.
FIIs, mutual funds find 9 smallcap stocks irresistible. Take a look!
FIIs have raised stake in Aegis Logistics from 15.03% in March 2022 to 16.4% in December 2022. Similarly, MF ownership has also gone up from 2.02% to 3.10%. In the last one year, the stock has rewarded investors with 116% return.
Q2 results this week: Bharti Airtel, Adani Ports, SBI, BoB and more
Bharti Airtel, 3i Infotech, Asahi India Glass, Castrol India, LT Foods, Larsen and Toubro, Saregama Industries, Swaraj Engines, Tata Steel, VST Tillers, Mold-Tek, TCI Express, Equitas Small Finance Bank, Motherson Sumi etc.
Buy Tatva Chintan Pharma Chem, target price Rs 2730: ICICI Securities
Tatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5047.54 Crore) operating in General sector.
Tatva Chintan plunges 7% after 56% YoY fall in Q1 profit
After the financial update, the scrip hit a day’s low of Rs 2161. At 11:05 am, it traded at Rs 2233.35 around 5.5 per cent below its previous close of Rs 2363.85. Promoters held 79.17 per cent stake in the firm while FIIs and DIIs held 3.53 per cent and 10.76 per cent stakes, respectively at the end of 30 June 2022, respectively.
Corporate Radar: Orient Cement to turn ex-dividend; Wipro Q1 results; ITC AGM, and more
Wipro, Havells India, IndusInd Bank, Gland Pharma, Tata Communications, Oracle Financial Services Software, Syngene International, Mastek, Ceat and Hathway Cable are among the companies that will announce their quarterly earnings today.
Corporate Radar: PNB, Union Bank to turn ex-dividend, SBI AGM; Q4 results, bonus issues & more
Wednesday is also the record date for dividends by Britannia Industries, Bank of Maharashtra, Agro Tech Foods, Bliss GVS Pharma, Bharat Seats and Morarka Finance.
More than half of 2021 debutants giving positive returns, 5 still hold multibagger status
Out of 64 companies listed in 2021, 34 are trading above their respective issue prices, with at least six of them still trading more than 100 per cent above their issue price. However, despite this stellar performance, the debutants of last year have dropped between 13-72 per cent from their all time peaks, with 10 of them eroding more than one third of investors' wealth.
Tatva Chintan Pharma sinks 10% as Q4 show disappoints
Earlier this month, ICICI Securities said it has a buy call on Tatva Chintan Pharma Chem with a target price of Rs 3,000. Time period given by the analyst is one year when Tatva Chintan Pharma Chem price can reach the defined target.
Corporate Radar: Muthoot Finance to trade ex-dividend, Mahindra CIE's AGM and more
Shares of Leading NBFC Muthoot Finance will trade ex-dividend today as the company had announced a dividend of Rs 20.
Buy Tatva Chintan Pharma Chem, target price Rs 3110: ICICI Securities
Tatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5757.71 Crore) operating in General sector.
Bottom-up investing: 4 stocks in near-monopoly business and superior margins
Companies with a clear niche and superior margins score on growth and value. ET has shortlisted four candidates.
Buy Tatva Chintan Pharma Chem, target price Rs 2920: ICICI Securities
Tatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5520.87 Crore) operating in General sector.
Tatva Chinta Pharma surges 11% as investors welcome industrial land buy in Gujarat
The step, seen as an indicator of growth prospects by investors, send the company’s scrip shooting up to a high of Rs 2,599.90 on the National Stock Exchange as against the previous close of Rs 2,338.55.
Stocks in the news: Go Fashion, PNB, Tatva Chintan, IRCTC and Reliance Capital
Go Fashion will make its Dalal Street Debut on Monday. The company sold its shares in the range of Rs 655-690 between November 17-22 to raise Rs 1,013.61 crore.
JM Financial Q2 results: Net profit up 25% at Rs 174 crore
The diversified financial services company posted a net profit of Rs 174.43 crore in the three-month period compared with Rs 139.06 crore in the corresponding period last year.
Tatva Chintan Pharma jumps 17%, hits 52-week high on strong Q2 show
The company's revenue from operations during the second quarter of the financial year 2021-22 (Q2FY22) surged 105.8 per cent YoY to Rs 123.6 crore. Meanwhile, the figure rose 16 per cent compared to the June 2021 quarter.
India's richie rich will have to shell out more to be in the IPO league
With the spate of recent issues resulting in money getting locked up and funded bets made on the last two offerings resulting in losses, finance companies have increased rates by as much as 200 basis points or 2% for IPO loans.
Biggest gainers & losers of the day: Tatva Chintan sees stellar debut; Ramco System tanks 12%
Tatva Chintan Pharma Chem doubled investors wealth on debut. Metal, retail chains and paper stocks, too, remained under the spotlight. Investors junked the poor performers of June 2021 quarter.
Stocks in the news: Tech Mahindra, Nestle, Tatva Chintan, MGL and Route Mobile
Tech Mahindra, Indus Towers, Colgate, CCI, Laurus Labs, TVS Motors, Oberoi Realty, Union Bank of India, LIC Housing will announce quarterly earnings today
Tatva Chintan IPO subscribed 180.4 times on Day 3; GMP spikes to 70%
Tatva Chintan Pharma Chem has already received bids worth Rs 149.99 crore from 22 anchor investors at the upper price band of Rs 1,083 per equity share.
Tatva Chintan to use IPO proceeds for growth, not to repay debt: Chintan Shah
“We would continue to spend 2% to 3% of revenue on R&D and that would translate into a strong top line growth.”
Chemplast Sanmar, Tatva Chintan Pharma Chem get Sebi nod for IPOs
Chemplast Sanmar and Tatva Chintan Pharma Chem obtained Sebi's observations on July 2 and June 30 respectively, an update with Sebi showed on Monday.
Load More
